November 1st 2024
A rapid reduction in E coli in the urine was observed among 10 of 16 evaluable patients at 4 hours following the first treatment.
September 9th 2024
Kidney stones linked to heart disease risk in women
July 29th 2013An analysis of data from three studies that involved a total of more than 240,000 participants found that a self-reported history of kidney stones was associated with a statistically significant increased risk of coronary heart disease among women.
Reduced OR, laser time observed with newer PVP system
May 24th 2013The new-generation GreenLight XPS-180W laser system (American Medical Systems, Minnetonka, MN) achieved an improved rate of tissue vaporization and overall efficacy in patients with BPH compared to an earlier generation laser, according to results of a recent multicenter study.
AUA 2013: Newer OAB agent viable alternative to antimuscarinics
May 7th 2013Data from a recent multicenter study provide new evidence that the beta-3 adrenoceptor agonist mirabegron (Myrbetriq) appears to be a viable alternative in patients with overactive bladder (OAB) who are poor responders to antimuscarinic agents or intolerant of their adverse events.
AUA 2013: ‘Lift’ procedure shows durable improvement in LUTS
May 7th 2013Men with symptomatic BPH had statistically significant, durable improvement in lower urinary tract symptoms (LUTS) following an office-based, minimally invasive prostatic urethral lift procedure, results of a pivotal randomized trial showed.
AUA 2013: Study: Women can take two steps to lower stone risk
May 4th 2013Postmenopausal women may reduce their risk of incident kidney stone disease by engaging in physical activity and avoiding excessive caloric intake, analyses of data collected in the Women’s Health Initiative Observational Study show.
Stone disease studies examine multiple causes
April 30th 2013With rates of stone disease on the rise in the U.S., researchers have turned their attention to possible causes. New research exploring the possible influence of diabetes, diet, and even being a surgeon will be presented at the upcoming AUA annual meeting.
Newer overactive bladder agent viable alternative to antimuscarinics
April 23rd 2013Data from a recent multicenter study provide new evidence that the beta-3 adrenoceptor agonist mirabegron (Myrbetriq) appears to be a viable alternative in patients with overactive bladder who are poor responders to antimuscarinic agents or intolerant of their adverse events.
Evolving algorithm for treating male voiding symptoms
April 18th 2013The algorithm for urologists’ approach to male voiding symptoms is evolving, according to Steven A. Kaplan, MD, of Weill Cornell Medical College, New York. This will be evident in presentations on BPH and lower urinary tract symptoms at the AUA annual meeting.